Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database
To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank te...
Saved in:
Published in | Clinical breast cancer Vol. 25; no. 6; pp. e739 - e749.e2 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.08.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.
We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.
BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).
BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.
This study compared prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) based on receptor subtypes using SEER registry data. Receptor subtype-based stratified survival analyses demonstrated that BSCC had a poorer survival in non-TNBC populations compared to BIDC, while BSCC-TNBC patients had similar survival to BIDC-TNBC. Notably, stage is a crucial prognostic factor for BSCC, more so than receptor subtype. These findings highlight that BSCC represents a highly aggressive malignancy, suggesting increased clinical attention in treatment strategies. |
---|---|
AbstractList | To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.OBJECTIVETo determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.MATERIALS AND METHODSWe extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).RESULTSBSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.CONCLUSIONBSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype. To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors. BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05). BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype. This study compared prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) based on receptor subtypes using SEER registry data. Receptor subtype-based stratified survival analyses demonstrated that BSCC had a poorer survival in non-TNBC populations compared to BIDC, while BSCC-TNBC patients had similar survival to BIDC-TNBC. Notably, stage is a crucial prognostic factor for BSCC, more so than receptor subtype. These findings highlight that BSCC represents a highly aggressive malignancy, suggesting increased clinical attention in treatment strategies. To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype. We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors. BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05). BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype. |
Author | Wang, Miao Xia, Yaoxiong Wu, Qiuji Guo, Xiaowan Li, Jie Qiu, Hui Hu, Kehua Gao, Yanping |
Author_xml | – sequence: 1 givenname: Miao surname: Wang fullname: Wang, Miao organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China – sequence: 2 givenname: Kehua surname: Hu fullname: Hu, Kehua organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China – sequence: 3 givenname: Yanping surname: Gao fullname: Gao, Yanping organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China – sequence: 4 givenname: Xiaowan surname: Guo fullname: Guo, Xiaowan organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China – sequence: 5 givenname: Jie surname: Li fullname: Li, Jie organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China – sequence: 6 givenname: Yaoxiong surname: Xia fullname: Xia, Yaoxiong email: 55490850@qq.com organization: Department of Radiotherapy, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China – sequence: 7 givenname: Hui surname: Qiu fullname: Qiu, Hui email: qiuhuiznyy@whu.edu.cn organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China – sequence: 8 givenname: Qiuji orcidid: 0000-0002-4655-3108 surname: Wu fullname: Wu, Qiuji email: wuqiuji@126.com organization: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40450500$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU2P0zAQhi20iP2AP8AB-cilwZ9Js-JSSqFIi0Ate7YmzmTXJbG7doJUiR-Pqy4cOIBkaXx4Hntm3kty5oNHQl5yVnDGyze7wvaNLQQTumCqYFw_IRe8lvMZK8vyLN-1KGdzwepzcpnSjjFRSs6ekXPFlGaasQvy82sMdz6k0Vm68NAfkks0dHQd4pB_oxu0uB9DTBR8S9erjaDO03cRIY10-zDBEKZEl9j3dAnROh8GuKYL-hlGe48t3Y5Te6C3yfk7Ot4j3a5WG_oeRmgg4XPytIM-4YvHekVuP6y-Ldezmy8fPy0XNzMrKj3OJHQVMKlBSW6Vbite11rn01XScrBS1V0tG5XHK-vGAjZ1JUrgSlihoBLyirw-vbuP4WHCNJrBJZt7Bo-5fSMF1_VcyEpl9NUjOjUDtmYf3QDxYH5vLAPiBNgYUorY_UE4M8dYzM4cYzHHWAxTJseSpbcnCfOUPxxGk6xDb7F1Ee1o2uD-rV__pdveeWeh_46H_8m_AF5Oprs |
Cites_doi | 10.1200/JCO.2004.00.9589 10.1200/JCO.2023.41.16_suppl.561 10.1097/PAS.0b013e3182877569 10.1007/BF02305666 10.1186/s12885-018-5212-x 10.1016/S1470-2045(19)30689-8 10.1007/s10549-017-4251-3 10.1016/j.humpath.2017.07.011 10.1002/jso.2930590313 10.1053/ejso.2002.1422 10.1007/s10549-014-3224-z 10.1056/NEJMoa053422 10.1016/j.critrevonc.2021.103223 10.1007/s12282-017-0768-x 10.1056/NEJMoa0802656 10.1007/s10549-020-05525-5 10.1016/j.jogoh.2018.06.007 10.1016/j.prp.2006.01.006 10.18632/oncotarget.7222 10.1177/000313480907501010 10.4103/jcrt.JCRT_303_17 10.1007/s12032-014-0172-8 10.1007/s00595-009-4276-2 10.1056/NEJMoa1809615 |
ContentType | Journal Article |
Copyright | 2025 Elsevier Inc. Copyright © 2025 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2025 Elsevier Inc. – notice: Copyright © 2025 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.clbc.2025.04.015 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1938-0666 |
EndPage | e749.e2 |
ExternalDocumentID | 40450500 10_1016_j_clbc_2025_04_015 S1526820925001065 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 6J9 6PF 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEGXH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBD EBS EFJIC EFKBS EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAYXX AFCTW AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c275t-3af7a035a431c45d719955955f73c1ac349f93b402669bcaeb9726a142c24a723 |
IEDL.DBID | .~1 |
ISSN | 1526-8209 1938-0666 |
IngestDate | Wed Jul 02 02:48:43 EDT 2025 Mon Jul 21 02:03:52 EDT 2025 Thu Jul 24 02:18:59 EDT 2025 Sat Aug 16 17:00:56 EDT 2025 Tue Aug 26 16:32:32 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Propensity score matching Breast cancer Prognosis Rare tumor Receptor subtype |
Language | English |
License | Copyright © 2025 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c275t-3af7a035a431c45d719955955f73c1ac349f93b402669bcaeb9726a142c24a723 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4655-3108 |
PMID | 40450500 |
PQID | 3215982374 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3215982374 pubmed_primary_40450500 crossref_primary_10_1016_j_clbc_2025_04_015 elsevier_sciencedirect_doi_10_1016_j_clbc_2025_04_015 elsevier_clinicalkey_doi_10_1016_j_clbc_2025_04_015 |
PublicationCentury | 2000 |
PublicationDate | 2025-08-01 |
PublicationDateYYYYMMDD | 2025-08-01 |
PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical breast cancer |
PublicationTitleAlternate | Clin Breast Cancer |
PublicationYear | 2025 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Schmid, Rugo, Adams (bib0028) 2020; 21 Oikawa, Igawa, Taguchi (bib0016) 2017; 24 Wu, Sun, Liu, Li, Lin, He (bib0010) 2016; 7 Benoist, Mureau, Joueidi (bib0019) 2018; 47 Hennessy, Krishnamurthy, Giordano (bib0011) 2005; 23 Stevenson, Graham, Khiyami, Mansour (bib0020) 1996; 3 Pirot, Chaltiel, Ben Lakhdar, Mathieu, Rimareix, Conversano (bib0007) 2020; 180 Ahmed, Idriss, Heiba, Sidi (bib0005) 2019; 33 Tavassoli (bib0003) 2003; 4 Chatha, Bano, Farooq, Farooq, Farooq, Zakaullah (bib0006) 2018; 28 Zhou, Chaudhry, Shah, Andrews (bib0014) 2018; 10 Grabowski, Saltzstein, Sadler, Blair (bib0017) 2009; 75 Liu, Yu, Sun (bib0022) 2015; 149 Honda, Saji, Horiguchi (bib0008) 2011; 41 Cao, Yue, Zhou (bib0024) 2019; 98 Schmid, Adams, Rugo (bib0027) 2018; 379 Behranwala, Nasiri, Abdullah, Trott, Gui (bib0018) 2003; 29 Bonner, Harari, Giralt (bib0025) 2006; 354 Zhu, Chen (bib0009) 2019; 19 Gupta, Malani, Weigand, Rangineni (bib0001) 2006; 202 Wang, Zhang, He (bib0023) 2014; 31 Vermorken, Mesia, Rivera (bib0026) 2008; 359 Dejager, Redlich, Dayer, Davis, Komorowski (bib0021) 1995; 59 Olsen, Keeney, Chen, Visscher, Carter (bib0013) 2017; 67 Soliman (bib0004) 2019; 15 Nayak, Wu, Gilcrease (bib0015) 2013; 37 Yadav, Yadav, Zakalik (bib0002) 2017; 164 Tarantino, Gandini, Trapani, Criscitiello, Curigliano (bib0029) 2021; 159 Ogita, Kubo, Kumamaru (bib0012) 2023; 41 Ahmed (10.1016/j.clbc.2025.04.015_bib0005) 2019; 33 Tavassoli (10.1016/j.clbc.2025.04.015_bib0003) 2003; 4 Nayak (10.1016/j.clbc.2025.04.015_bib0015) 2013; 37 Olsen (10.1016/j.clbc.2025.04.015_bib0013) 2017; 67 Cao (10.1016/j.clbc.2025.04.015_bib0024) 2019; 98 Schmid (10.1016/j.clbc.2025.04.015_bib0028) 2020; 21 Pirot (10.1016/j.clbc.2025.04.015_bib0007) 2020; 180 Zhu (10.1016/j.clbc.2025.04.015_bib0009) 2019; 19 Gupta (10.1016/j.clbc.2025.04.015_bib0001) 2006; 202 Zhou (10.1016/j.clbc.2025.04.015_bib0014) 2018; 10 Oikawa (10.1016/j.clbc.2025.04.015_bib0016) 2017; 24 Behranwala (10.1016/j.clbc.2025.04.015_bib0018) 2003; 29 Soliman (10.1016/j.clbc.2025.04.015_bib0004) 2019; 15 Honda (10.1016/j.clbc.2025.04.015_bib0008) 2011; 41 Bonner (10.1016/j.clbc.2025.04.015_bib0025) 2006; 354 Yadav (10.1016/j.clbc.2025.04.015_bib0002) 2017; 164 Hennessy (10.1016/j.clbc.2025.04.015_bib0011) 2005; 23 Wu (10.1016/j.clbc.2025.04.015_bib0010) 2016; 7 Liu (10.1016/j.clbc.2025.04.015_bib0022) 2015; 149 Dejager (10.1016/j.clbc.2025.04.015_bib0021) 1995; 59 Ogita (10.1016/j.clbc.2025.04.015_bib0012) 2023; 41 Wang (10.1016/j.clbc.2025.04.015_bib0023) 2014; 31 Stevenson (10.1016/j.clbc.2025.04.015_bib0020) 1996; 3 Benoist (10.1016/j.clbc.2025.04.015_bib0019) 2018; 47 Vermorken (10.1016/j.clbc.2025.04.015_bib0026) 2008; 359 Tarantino (10.1016/j.clbc.2025.04.015_bib0029) 2021; 159 Schmid (10.1016/j.clbc.2025.04.015_bib0027) 2018; 379 Chatha (10.1016/j.clbc.2025.04.015_bib0006) 2018; 28 Grabowski (10.1016/j.clbc.2025.04.015_bib0017) 2009; 75 |
References_xml | – volume: 149 start-page: 133 year: 2015 end-page: 140 ident: bib0022 article-title: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast publication-title: Breast Cancer Res Treat – volume: 4 start-page: 100 year: 2003 end-page: 103 ident: bib0003 article-title: WHO classification of tumors. Tumors of the breast and female genital organs publication-title: Lyon IRAC – volume: 7 start-page: 10684 year: 2016 end-page: 10693 ident: bib0010 article-title: Effect of postoperative radiotherapy for squamous cell cancer of the breast in a surveillance epidemiology and end results population-based study publication-title: Oncotarget – volume: 10 start-page: e3405 year: 2018 ident: bib0014 article-title: Breast squamous cell carcinoma following breast augmentation publication-title: Cureus – volume: 21 start-page: 44 year: 2020 end-page: 59 ident: bib0028 article-title: Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol – volume: 19 start-page: 26 year: 2019 ident: bib0009 article-title: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis publication-title: BMC Cancer – volume: 202 start-page: 465 year: 2006 end-page: 469 ident: bib0001 article-title: Pure primary squamous cell carcinoma of the breast: a rare presentation and clinicopathologic comparison with usual ductal carcinoma of the breast publication-title: Pathol Res Pract – volume: 67 start-page: 94 year: 2017 end-page: 100 ident: bib0013 article-title: Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases publication-title: Hum Pathol – volume: 359 start-page: 1116 year: 2008 end-page: 1127 ident: bib0026 article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer publication-title: N Engl J Med – volume: 379 start-page: 2108 year: 2018 end-page: 2121 ident: bib0027 article-title: Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer publication-title: N Engl J Med – volume: 24 start-page: 733 year: 2017 end-page: 741 ident: bib0016 article-title: Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity publication-title: Breast Cancer – volume: 47 start-page: 275 year: 2018 end-page: 280 ident: bib0019 article-title: Management and prognosis of pure primary squamous cell carcinoma of the breast publication-title: J Gynecol Obstet Hum Reprod – volume: 28 start-page: 776 year: 2018 end-page: 778 ident: bib0006 article-title: Squamous cell carcinoma of the breast publication-title: J Coll Physicians Surg Pak – volume: 41 start-page: 561 year: 2023 ident: bib0012 article-title: Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: the Japanese breast cancer registry analysis publication-title: Journal of Clinical Oncology – volume: 164 start-page: 201 year: 2017 end-page: 208 ident: bib0002 article-title: Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival publication-title: Breast Cancer Res Treat – volume: 23 start-page: 7827 year: 2005 end-page: 7835 ident: bib0011 article-title: Squamous cell carcinoma of the breast publication-title: J Clin Oncol – volume: 31 start-page: 172 year: 2014 ident: bib0023 article-title: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast publication-title: Med Oncol – volume: 59 start-page: 199 year: 1995 end-page: 203 ident: bib0021 article-title: Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy publication-title: J Surg Oncol – volume: 41 start-page: 328 year: 2011 end-page: 332 ident: bib0008 article-title: Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast publication-title: Surg Today – volume: 37 start-page: 867 year: 2013 end-page: 873 ident: bib0015 article-title: Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival publication-title: Am J Surg Pathol – volume: 354 start-page: 567 year: 2006 end-page: 578 ident: bib0025 article-title: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck publication-title: N Engl J Med – volume: 15 start-page: 1057 year: 2019 end-page: 1061 ident: bib0004 article-title: Squamous cell carcinoma of the breast: a retrospective study publication-title: J Cancer Res Ther – volume: 180 start-page: 87 year: 2020 end-page: 95 ident: bib0007 article-title: Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? a series of 39 patients publication-title: Breast Cancer Res Treat – volume: 75 start-page: 914 year: 2009 end-page: 917 ident: bib0017 article-title: Squamous cell carcinoma of the breast: a review of 177 cases publication-title: Am Surg – volume: 33 start-page: 143 year: 2019 ident: bib0005 article-title: [Squamous cell carcinoma of the breast: a case study conducted in Mauritania] publication-title: Pan Afr Med J – volume: 29 start-page: 386 year: 2003 end-page: 389 ident: bib0018 article-title: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome publication-title: Eur J Surg Oncol – volume: 3 start-page: 367 year: 1996 end-page: 374 ident: bib0020 article-title: Squamous cell carcinoma of the breast: a clinical approach publication-title: Ann Surg Oncol – volume: 98 year: 2019 ident: bib0024 article-title: Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: a case report publication-title: Medicine (Baltimore) – volume: 159 year: 2021 ident: bib0029 article-title: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials publication-title: Crit Rev Oncol Hematol – volume: 4 start-page: 100 year: 2003 ident: 10.1016/j.clbc.2025.04.015_bib0003 article-title: WHO classification of tumors. Tumors of the breast and female genital organs publication-title: Lyon IRAC – volume: 23 start-page: 7827 year: 2005 ident: 10.1016/j.clbc.2025.04.015_bib0011 article-title: Squamous cell carcinoma of the breast publication-title: J Clin Oncol doi: 10.1200/JCO.2004.00.9589 – volume: 41 start-page: 561 year: 2023 ident: 10.1016/j.clbc.2025.04.015_bib0012 article-title: Prognosis of squamous cell carcinoma of the breast by biological subtypes and the efficacy of radiotherapy: the Japanese breast cancer registry analysis publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2023.41.16_suppl.561 – volume: 98 year: 2019 ident: 10.1016/j.clbc.2025.04.015_bib0024 article-title: Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: a case report publication-title: Medicine (Baltimore) – volume: 37 start-page: 867 year: 2013 ident: 10.1016/j.clbc.2025.04.015_bib0015 article-title: Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3182877569 – volume: 3 start-page: 367 year: 1996 ident: 10.1016/j.clbc.2025.04.015_bib0020 article-title: Squamous cell carcinoma of the breast: a clinical approach publication-title: Ann Surg Oncol doi: 10.1007/BF02305666 – volume: 19 start-page: 26 year: 2019 ident: 10.1016/j.clbc.2025.04.015_bib0009 article-title: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis publication-title: BMC Cancer doi: 10.1186/s12885-018-5212-x – volume: 21 start-page: 44 year: 2020 ident: 10.1016/j.clbc.2025.04.015_bib0028 article-title: Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30689-8 – volume: 164 start-page: 201 year: 2017 ident: 10.1016/j.clbc.2025.04.015_bib0002 article-title: Squamous cell carcinoma of the breast in the United States: incidence, demographics, tumor characteristics, and survival publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4251-3 – volume: 67 start-page: 94 year: 2017 ident: 10.1016/j.clbc.2025.04.015_bib0013 article-title: Breast implant capsule-associated squamous cell carcinoma: a report of 2 cases publication-title: Hum Pathol doi: 10.1016/j.humpath.2017.07.011 – volume: 59 start-page: 199 year: 1995 ident: 10.1016/j.clbc.2025.04.015_bib0021 article-title: Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy publication-title: J Surg Oncol doi: 10.1002/jso.2930590313 – volume: 29 start-page: 386 year: 2003 ident: 10.1016/j.clbc.2025.04.015_bib0018 article-title: Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome publication-title: Eur J Surg Oncol doi: 10.1053/ejso.2002.1422 – volume: 149 start-page: 133 year: 2015 ident: 10.1016/j.clbc.2025.04.015_bib0022 article-title: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-014-3224-z – volume: 354 start-page: 567 year: 2006 ident: 10.1016/j.clbc.2025.04.015_bib0025 article-title: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck publication-title: N Engl J Med doi: 10.1056/NEJMoa053422 – volume: 33 start-page: 143 year: 2019 ident: 10.1016/j.clbc.2025.04.015_bib0005 article-title: [Squamous cell carcinoma of the breast: a case study conducted in Mauritania] publication-title: Pan Afr Med J – volume: 159 year: 2021 ident: 10.1016/j.clbc.2025.04.015_bib0029 article-title: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2021.103223 – volume: 24 start-page: 733 year: 2017 ident: 10.1016/j.clbc.2025.04.015_bib0016 article-title: Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity publication-title: Breast Cancer doi: 10.1007/s12282-017-0768-x – volume: 359 start-page: 1116 year: 2008 ident: 10.1016/j.clbc.2025.04.015_bib0026 article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0802656 – volume: 180 start-page: 87 year: 2020 ident: 10.1016/j.clbc.2025.04.015_bib0007 article-title: Squamous cell carcinoma of the breast, are there two entities with distinct prognosis? a series of 39 patients publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-020-05525-5 – volume: 10 start-page: e3405 year: 2018 ident: 10.1016/j.clbc.2025.04.015_bib0014 article-title: Breast squamous cell carcinoma following breast augmentation publication-title: Cureus – volume: 47 start-page: 275 year: 2018 ident: 10.1016/j.clbc.2025.04.015_bib0019 article-title: Management and prognosis of pure primary squamous cell carcinoma of the breast publication-title: J Gynecol Obstet Hum Reprod doi: 10.1016/j.jogoh.2018.06.007 – volume: 202 start-page: 465 year: 2006 ident: 10.1016/j.clbc.2025.04.015_bib0001 article-title: Pure primary squamous cell carcinoma of the breast: a rare presentation and clinicopathologic comparison with usual ductal carcinoma of the breast publication-title: Pathol Res Pract doi: 10.1016/j.prp.2006.01.006 – volume: 7 start-page: 10684 year: 2016 ident: 10.1016/j.clbc.2025.04.015_bib0010 article-title: Effect of postoperative radiotherapy for squamous cell cancer of the breast in a surveillance epidemiology and end results population-based study publication-title: Oncotarget doi: 10.18632/oncotarget.7222 – volume: 75 start-page: 914 year: 2009 ident: 10.1016/j.clbc.2025.04.015_bib0017 article-title: Squamous cell carcinoma of the breast: a review of 177 cases publication-title: Am Surg doi: 10.1177/000313480907501010 – volume: 15 start-page: 1057 year: 2019 ident: 10.1016/j.clbc.2025.04.015_bib0004 article-title: Squamous cell carcinoma of the breast: a retrospective study publication-title: J Cancer Res Ther doi: 10.4103/jcrt.JCRT_303_17 – volume: 31 start-page: 172 year: 2014 ident: 10.1016/j.clbc.2025.04.015_bib0023 article-title: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast publication-title: Med Oncol doi: 10.1007/s12032-014-0172-8 – volume: 41 start-page: 328 year: 2011 ident: 10.1016/j.clbc.2025.04.015_bib0008 article-title: Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast publication-title: Surg Today doi: 10.1007/s00595-009-4276-2 – volume: 379 start-page: 2108 year: 2018 ident: 10.1016/j.clbc.2025.04.015_bib0027 article-title: Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1809615 – volume: 28 start-page: 776 year: 2018 ident: 10.1016/j.clbc.2025.04.015_bib0006 article-title: Squamous cell carcinoma of the breast publication-title: J Coll Physicians Surg Pak |
SSID | ssj0026310 |
Score | 2.408646 |
Snippet | To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.... To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e739 |
SubjectTerms | Adult Aged Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - mortality Carcinoma, Ductal, Breast - pathology Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Female Humans Incidence Kaplan-Meier Estimate Middle Aged Prognosis Propensity Score Propensity score matching Rare tumor Receptor subtype Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism SEER Program - statistics & numerical data Survival Rate Triple Negative Breast Neoplasms - epidemiology Triple Negative Breast Neoplasms - mortality Triple Negative Breast Neoplasms - pathology |
Title | Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1526820925001065 https://dx.doi.org/10.1016/j.clbc.2025.04.015 https://www.ncbi.nlm.nih.gov/pubmed/40450500 https://www.proquest.com/docview/3215982374 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhgdJLafrcNglT6K2469Uz6m2z3eC2JJRsA7kJSZZhw9a7Dc6hUPrbO-PHQqAPKPhiW8JCI898I30zw9hrK1UItGsTpUmZjOizWi1DNqlkpY6Flnlqs32e6-JSfrxSVztsNsTCEK2y1_2dTm-1df9k3M_meLNcjhcTylTCc4tGnBwbCjSX0tAqf_tzS_PgWnQZCbBxRq37wJmO4xVXgdIYctWmO6XSuL83Tn8Cn60ROn3IHvToEabdAPfZTqofsXtn_fn4Y_bj882amHP4GoZ0I7CuoEBkuq4TIEhMG6qvA74uoZhfcFjWcELE9AYW3249bQTALK1WMKMiQ_X6q38HUzjzJNwSiHX4HVqaASByhMV8fgHvfePJGD5hl6fzL7Mi6-srZJEb1WTCV8bnQnkEEVGq0lC4tsKrMiJOfBTSVlYE9DC1tiH6FKzh2k8kj1x6w8VTtlvj4J8zKCsdDX5LhJik0OQnmdweRxGEL_MyjNibYWLdpkuj4QZ-2bUjMTgSg8ulQzGMmBjm3g0BoqjSHGr5v_ZS2153ltA_-70axOvw36IDE18nnG4nEA9ZyuYjR-xZJ_ft6CVi4RxX3ov__OpLdp_uOi7hAdttbm7TIeKbJhy1C_iI7U0_fCrOfwE3u_Z6 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBapA20voc_U6WsKvZXF69Ur6s11HTZNbEqcQG5C0mrBxV27YXMo9Md3Zh-GQh9Q2NNqB4kZ7cw30ugTY2-NkN7Tqk0QOiYiYM5qlPDJuBSlPOZKpLFh-1yo_Ep8upbXe2zan4WhssrO97c-vfHW3ZtRp83RdrUaLcfEVJKlBoM4JTbyDtsndio5YPuT07N8scu7FG9JCfD7hAS6szNtmVdYe2IyzGTDeEq34_4-Pv0JfzZx6OQBO-gAJEzaMT5ke7F6xO7Ouy3yx-zH55sNFc9hM_SMI7ApIUdwuqkiIE6MW7piB1xVQD67yGBVwQeqTa9h-e3W0VoATON6DVO6Z6jafHXvYQJzR_YtgAoPv0NTaQAIHmE5m13AR1c7iodP2NXJ7HKaJ90VC0nItKwT7krtUi4d4oggZKHpxLbEp9Q8jF3gwpSGe0wylTI-uOiNzpQbiyxkwumMP2WDCgf_jEFRqqCxL-5DFFxRqqRTcxy4565ICz9k73rF2m3LpGH7ErMvlsxgyQw2FRbNMGS8173tz4iiV7Po6P8qJXdSv8yif8q96c1r8feiPRNXRVS35QiJDBH6iCE7bO2-G71AOJzi5Dv6z15fs3v55fzcnp8uzp6z-9TSlha-YIP65ja-RLhT-1fddP4Jr9z5Kw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Analysis+of+Hormone+Receptors+and+HER2+in+Breast+Squamous+Cell+Carcinoma%3A+A+Matched+Study+Using+the+SEER+Database&rft.jtitle=Clinical+breast+cancer&rft.au=Wang%2C+Miao&rft.au=Hu%2C+Kehua&rft.au=Gao%2C+Yanping&rft.au=Guo%2C+Xiaowan&rft.date=2025-08-01&rft.pub=Elsevier+Inc&rft.issn=1526-8209&rft.volume=25&rft.issue=6&rft.spage=e739&rft.epage=e749.e2&rft_id=info:doi/10.1016%2Fj.clbc.2025.04.015&rft.externalDocID=S1526820925001065 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1526-8209&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1526-8209&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1526-8209&client=summon |